Predicting heart problems in breast cancer patients receiving chemotherapy
Official title: Early Prediction and Warning for Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy: a Prospective, Multicenter, Clinical Trial
Run by First Hospital of China Medical University · NCT06282796 · Data updated 2026-11-12
This study is trying to see if a new way of monitoring heart function can help breast cancer patients receiving certain chemotherapy drugs catch heart problems early and improve their health outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | Women only |
| Enrollment | 600 (estimated) |
| Sponsor | First Hospital of China Medical University Academic / other |
| Drugs / interventions | trastuzumab, chemotherapy, radiation |
| Locations | 5 sites (Fuzhou, Fujian and 4 other locations) |
| Status | Recruiting |
| Started | January 1, 2024 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2028 |
| Registry record updated | February 28, 2024 |
| Trial ID | NCT06282796 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older with confirmed stage I-III HER2+ breast cancer who are scheduled to receive anthracycline chemotherapy.
✕Probably not a fit
Patients with a life expectancy of 12 months or less, those participating in other oncology trials, or those with prior anthracycline treatment may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This multicenter observational study aims to develop an intelligent model for the early prediction and warning of cardiotoxicity in patients undergoing anthracycline-based chemotherapy for breast cancer. By utilizing echocardiography to monitor changes in left ventricular ejection fraction and global longitudinal strain, the study seeks to identify asymptomatic cardiac dysfunction early, allowing for timely intervention. The goal is to improve patient outcomes by reducing the risk of chemotherapy-related cardiac issues, which can significantly impact survival rates. The findings could provide a theoretical basis for targeted myocardial protection strategies during treatment.
Why it matters
Potential benefit: If successful, this study could lead to improved monitoring and prevention of heart-related complications in breast cancer patients undergoing chemotherapy.
How similar studies have gone: While the approach of using echocardiography for early detection of cardiotoxicity is established, the development of an intelligent predictive model in this specific context is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥18 years * Histologically or cytopathological confirmed stage I-III HER2+ breast cancer, scheduled to receive consecutive anthracycline chemotherapy or subsequent sequential trastuzumab targeted therapy * LVEF≥53% before chemotherapy Exclusion Criteria: * life expectancy ≤12 months * Participating in other ongoing oncology clinical trials * Prior treatment with anthracyclines or chest radiation therapy * Pregnant or lactating women * Ultrasound images of the heart are of very poor quality
Where it's running
-
Fujian Cancer Hospital
Fuzhou, Fujian, China Recruiting -
Dalian Friendship Hospital
Dalian, Liaoning, China Recruiting -
Dalian Municipal Central Hospital
Dalian, Liaoning, China Recruiting -
Liaoning Cancer Hospital & Institute
Shenyang, Liaoning, China Recruiting -
The Third People's Hospital Of Chengdu
Chengdu, Sichuan, China Recruiting
Study contacts
- Principal investigator: Yonghuai Wang, Ph.D — the First Hospital of China Medical Univeristy
- Study coordinator: Yonghuai Wang, Ph.D
- Email: wyh_wyh2012@163.com
- Phone: +86 15998323056
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Gyrotonic exercise for elders with breast cancer and Behcet disease
We’re testing whether a gyrotonic exercise program helps older people who have both Behcet disease and breast cancer.
-
PECS II vs SPSIP nerve blocks for pain after mastectomy
This study tests whether two ultrasound-guided nerve blocks (PECS II and SPSIP) differ in how much opioid patients need after mastectomy.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
Compare a new endoscopy-assisted breast-conserving surgery with the usual approach
This study tests whether a new endoscopy-assisted breast-conserving technique can provide similar or better cosmetic outcomes and safety compared with conventional breast-conserving surgery in women with early breast cancer who want to preserve their breast.
-
Different skin care approaches to prevent skin reactions after mastectomy radiation
This study tests three standard skin care methods to see which best prevents radiation dermatitis in people who had a mastectomy and are receiving post-mastectomy radiation therapy.
-
3D Heart Strain to Detect Early Cardiotoxicity in Cancer Therapy
This study tests whether 3D echocardiography can detect early heart damage from cancer treatments like anthracyclines or HER2-targeted therapy better than standard 2D methods.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.